Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Keith T. Flaherty, Florentia Mina et al.|EClinicalMedicine|2023Cited by 26
Meeting Report: 47th Annual Meeting of the “Arbeitsgemeinschaft Dermatologische Forschung”Georg Stary, Timo Buhl, Mario Fabri et al.|Experimental Dermatology|2022Cited by 0